You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 16, Issue 4

February-2 2024 - 163 articles

Cover Story: Epiregulin (EREG), a member of the EGF family, binds to the EGFR and ErbB4, and it stimulates EGFR-related downstream pathways. Increasing evidence indicates that EREG plays a pivotal role in the development of many human cancers, including non-small cell lung cancer. EREG overexpression is induced by activating mutations in the EGFR, KRAS, and BRAF and contributes to the aggressive phenotypes of non-small cell lung cancer with such oncogenic drivers. Recent studies have elucidated the roles of EREG in a tumor microenvironment, including the epithelial–mesenchymal transition, angiogenesis, immune evasion, and resistance to anticancer therapy. Here, we summarized the current understanding of EREG as an oncogene and discussed its oncogenic role in lung tumorigenesis and therapeutic resistance. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (163)

  • Article
  • Open Access
2 Citations
2,861 Views
19 Pages

The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment

  • Zhan Zhuang,
  • Jinglin Zhou,
  • Minglian Qiu,
  • Jiamian Li,
  • Zhuangheng Lin,
  • Huihan Yi,
  • Xuerong Liu,
  • Changyu Huang,
  • Binghua Tang and
  • Bo Liu
  • + 1 author

19 February 2024

In solid tumors, the formidable anti-tumor impact resulting from blocking the “don’t eat me” signal, arising from CD47–SIRPα interaction, is constrained, especially compared to its efficacy in hematopoietic malignancies....

  • Review
  • Open Access
23 Citations
6,358 Views
15 Pages

Artificial Intelligence-Based Treatment Decisions: A New Era for NSCLC

  • Oraianthi Fiste,
  • Ioannis Gkiozos,
  • Andriani Charpidou and
  • Nikolaos K. Syrigos

19 February 2024

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality among women and men, in developed countries, despite the public health interventions including tobacco-free campaigns, screening and early detection methods, recent t...

  • Article
  • Open Access
3 Citations
2,443 Views
13 Pages

Knockdown of Antisense Noncoding Mitochondrial RNA Reduces Tumorigenicity of Patient-Derived Clear Cell Renal Carcinoma Cells in an Orthotopic Xenograft Mouse Model

  • Mariela Araya,
  • Francisca Sepúlveda,
  • Jaime Villegas,
  • Luis Alarcón,
  • Luis O. Burzio,
  • Verónica A. Burzio and
  • Vincenzo Borgna

19 February 2024

Clear cell renal cell carcinoma (ccRCC) is the most prevalent form of renal cancer and its treatment is hindered by a resistance to targeted therapies, immunotherapies and combinations of both. We have reported that the knockdown of the antisense non...

  • Editorial
  • Open Access
2 Citations
2,020 Views
5 Pages

Clear Cell Renal Cell Carcinoma: A Test Bench for Investigating Tumor Complexity

  • Claudia Manini,
  • Estíbaliz López-Fernández,
  • Gorka Larrinaga and
  • José I. López

19 February 2024

Clear cell renal cell carcinoma (CCRCC), by far the most common renal cancer subtype, is an aggressive tumor variant, serving in recent years as a prolific test bench in cancer research [...]

  • Article
  • Open Access
20 Citations
2,651 Views
14 Pages

Prognostic Value of Inflammatory Burden Index in Advanced Gastric Cancer Patients Undergoing Multimodal Treatment

  • Zuzanna Pelc,
  • Katarzyna Sędłak,
  • Radosław Mlak,
  • Magdalena Leśniewska,
  • Katarzyna Mielniczek,
  • Piotr Rola,
  • Jacek Januszewski,
  • Olena Zhaldak,
  • Anna Rekowska and
  • Katarzyna Gęca
  • + 4 authors

18 February 2024

Since increasing evidence underlines the prominent role of systemic inflammation in carcinogenesis, the inflammation burden index (IBI) has emerged as a promising biomarker to estimate survival outcomes among cancer patients. The IBI has only been va...

  • Review
  • Open Access
8 Citations
7,031 Views
25 Pages

Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma

  • Ali Al Sbihi,
  • Maryam Alasfour and
  • Georgios Pongas

18 February 2024

Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates a...

  • Article
  • Open Access
1 Citations
2,737 Views
21 Pages

ncRNAs Orchestrate Chemosensitivity Induction by Neddylation Blockades

  • Andrea Pérez-González,
  • Ivonne Ramírez-Díaz,
  • Josué Guzmán-Linares,
  • Pouya Sarvari,
  • Pourya Sarvari and
  • Karla Rubio

18 February 2024

We performed an integrative transcriptomic in silico analysis using lung adenocarcinoma A549 cells treated with the neddylation inhibitor MLN4924 and the gefitinib-resistant PC9 cell line (PC9GR). We focused on the transcriptional effects of the top...

  • Article
  • Open Access
1 Citations
3,310 Views
15 Pages

Baseline IgM Amounts Can Identify Patients with Poor Outcomes: Results from a Real-Life Single-Center Study on Classical Hodgkin Lymphoma

  • Andrea Duminuco,
  • Gabriella Santuccio,
  • Annalisa Chiarenza,
  • Amalia Figuera,
  • Giovanna Motta,
  • Anastasia Laura Caruso,
  • Alessandro Petronaci,
  • Massimo Ippolito,
  • Claudio Cerchione and
  • Francesco Di Raimondo
  • + 1 author

18 February 2024

Hodgkin Lymphoma (HL) is characterized by an inflammatory background in which the reactive myeloid cells may exert an immune-suppressive effect related to the progression of the disease. Immunoglobulin M is the first antibody isotype produced during...

  • Article
  • Open Access
5 Citations
3,930 Views
21 Pages

Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma

  • Carlo Caputo,
  • Michela Falco,
  • Anna Grimaldi,
  • Angela Lombardi,
  • Chiara Carmen Miceli,
  • Mariateresa Cocule,
  • Marco Montella,
  • Luca Pompella,
  • Giuseppe Tirino and
  • Severo Campione
  • + 14 authors

18 February 2024

Pancreatic ductal adenocarcinoma (PDAC), a neoplasm of the gastrointestinal tract, is the most common pancreatic malignancy (90%) and the fourth highest cause of cancer mortality worldwide. Surgery intervention is currently the only strategy able to...

  • Review
  • Open Access
13 Citations
4,797 Views
24 Pages

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy

  • Song Yang,
  • Yumeng Sun,
  • Wei Liu,
  • Yi Zhang,
  • Guozhu Sun,
  • Bai Xiang and
  • Jiankai Yang

18 February 2024

Gliomas, the most prevalent primary malignant brain tumors, present a challenging prognosis even after undergoing surgery, radiation, and chemotherapy. Exosomes, nano-sized extracellular vesicles secreted by various cells, play a pivotal role in glio...

of 17

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694